---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-266705"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2026-06-11T11:35:16+00:00"
generated_at: "2026-06-11T11:40:11.272532+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics reports durable phlebotomy reduction and QoL gains from Phase 1 divesiran study at EHA 2026

## Summary
- 21 PV patients: 5 phlebotomies during active treatment vs 80 in prior 6 months; only 4 in 16-week follow-up.
- Median time to first phlebotomy was 287 days among 14 evaluable patients.
- Majority had improved MPN-10 symptom scores through Week 34, indicating better quality of life.
- Phase 2 SANRECO (Q6W and Q12W dosing) topline results expected August 2026.
- Divesiran well tolerated; mild injection-site reactions, no treatment-related SAEs or discontinuations.

## SEC filing metadata
- accession: 0001193125-26-266705
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2026-06-11T11:35:16+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312526266705/0001193125-26-266705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312526266705/sln-20260611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-266705
- JSON: https://secwatch.observer/filing/0001193125-26-266705.json
- Plain text: https://secwatch.observer/filing/0001193125-26-266705.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.